Last updated: March 13, 2026
What is NDC 42806-0267?
NDC 42806-0267 refers to a specific pharmaceutical product listed in the National Drug Code (NDC) directory. The product is Benlysta (belimumab), a monoclonal antibody used in the treatment of systemic lupus erythematosus (SLE).
Market Landscape
Indications and Usage
Benlysta is approved for adult patients with active SLE. The drug is administered via intravenous infusion or subcutaneous injection, depending on the formulation.
Market Size
As of 2022, the global lupus therapeutics market value was approximately $1.2 billion. Benlysta holds a significant market share, backed by its first-in-class status and FDA approval since 2011.
Competitive Environment
Main competitors include:
- Anifrolumab (Saphnelo) – FDA approved in 2021
- Methotrexate – off-label use for SLE
- Mycophenolate mofetil – off-label, immunosuppressant
Although these alternatives address SLE symptoms, Benlysta's targeted mechanism of action maintains its premium positioning.
Market Trends
- Steady uptake driven by increased diagnosis of SLE and recognition of the drug’s efficacy.
- Growing preference for subcutaneous form, which offers convenience.
- Potential expansion into pediatric and other autoimmune indications.
Price Analysis
Historical Pricing
The average wholesale price (AWP) of Benlysta has varied:
| Year |
IV Form (per infusion) |
SC Form (per injection) |
| 2020 |
$3,185 |
$2,079 |
| 2022 |
$3,245 |
$2,150 |
Current Pricing (2023)
- Intravenous (IV): approximately $3,250 per infusion.
- Subcutaneous (SC): approximately $2,150 per injection.
Prices have remained relatively stable over the past two years, with slight increases aligned with inflation and manufacturing costs.
Reimbursement and Pricing Policy
Medicare and private insurers typically negotiate rebates, affecting net prices. Average reimbursement rates are estimated at 70-80% of wholesale prices.
Cost Comparison
Compared to alternative immunosuppressants:
- Methotrexate: under $50/month
- Mycophenolate mofetil: approximately $1,200/month
Benlysta’s annual treatment cost exceeds $30,000, positioning it as a high-cost therapy primarily justified by its targeted immunomodulatory profile.
Future Price Projections
Factors Influencing Pricing
- Patent expiration: No scheduled patent expiration before 2030, maintaining market exclusivity.
- Market penetration: Increased adoption may stabilize prices.
- Manufacturing costs: Biosimilar development could reduce prices; however, no biosimilars approved yet.
- Insurance policies: Reimbursement strategies influence net prices.
Price Outlook (Next 3-5 Years)
| Year |
Predicted Price Range |
Rationale |
| 2024 |
$3,200 - $3,400 |
Stable pricing with minor inflation adjustments |
| 2025 |
$3,250 - $3,500 |
Increased market penetration; potential policy impacts |
| 2026 |
$3,300 - $3,600 |
Biosimilar entry unlikely before 2027; market stabilization |
Key Market Risks
- Emergence of biosimilars could lower prices.
- Regulatory changes affecting reimbursement policies.
- Competition from new therapies or expanded indications.
Summary
Benlysta (NDC 42806-0267) commands a high price point, reflecting its role as a targeted biological therapy for SLE. Market stability is expected over the next five years, with modest price increases unless biosimilars enter the market or reimbursement policies change significantly.
Key Takeaways
- NDC 42806-0267 corresponds to Benlysta, a leading biologic for SLE.
- Its annual treatment cost is approximately $30,000, with stable pricing expected.
- Biosimilar competition anticipated post-2027 could impact prices.
- Market trends favor increased usage, supporting sustained pricing.
- Reimbursement negotiations significantly influence net revenue prospects.
FAQs
-
When is biosimilar competition expected for Benlysta?
Biosimilars are unlikely before 2027, contingent on patent protections and regulatory approval.
-
How does Benlysta’s price compare to other lupus treatments?
It is significantly more expensive than traditional immunosuppressants but offers targeted efficacy.
-
What factors could reduce the price of Benlysta?
Biosimilar market entries and shifts in reimbursement policies.
-
Are there updates regarding new indications for Benlysta?
Ongoing research targets additional autoimmune diseases, which could expand its use.
-
How does insurance reimbursement impact net revenue?
Reimbursements typically cover about 70-80% of list prices, affecting actual revenue.
Sources
[1] IQVIA. (2023). Market Data for Lupus Therapeutics.
[2] US Food and Drug Administration. (2011). FDA Approval of Benlysta.
[3] Research and Markets. (2022). Global Lupus Therapeutics Market Report.
